(2S,2'S)-N,N'-(1,4-哌嗪二基二-3,1-丙烷二基)二[2-氨基-5-[(氨基亚胺甲基)氨基]戊酰胺] | 1438492-26-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S,2'S)-N,N'-(1,4-哌嗪二基二-3,1-丙烷二基)二[2-氨基-5-[(氨基亚胺甲基)氨基]戊酰胺]
• 英文名称: 2-amino-5-guanidino-pentanoic acid (3'-{4-[3-(2-amino-5-guanidino-pentanoylamino)-propyl]-piperazin-1-yl}-propyl)-amide
• 英文别名: ciraparantag；N¹,N¹'-[piperazine-1,4-diylbis(propane-1,3-diyl)]bis-L-argininamide；di-arginine piperazine；Ciraparantag；(2S)-2-amino-N-[3-[4-[3-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propyl]piperazin-1-yl]propyl]-5-(diaminomethylideneamino)pentanamide
• CAS: 1438492-26-2
• 化学式: C₂₂H₄₈N₁₂O₂
• 分子量: 512.702
• InChiKey: HRDUUSCYRPOMSO-ROUUACIJSA-N

物化性质

• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4
• 重原子数：
  36
• 可旋转键数：
  18
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  246
• 氢给体数：
  8
• 氢受体数：
  8

安全信息

• 储存条件：
  | 2-8℃ |

制备方法与用途

Ciraparantag是一种针对凝血酶和因子Xa的抑制剂，能够对抗除维生素K拮抗剂(VKAs)之外的所有凝血因子。

反应信息

• 作为产物：
  描述：

  生成 (2S,2'S)-N,N'-(1,4-哌嗪二基二-3,1-丙烷二基)二[2-氨基-5-[(氨基亚胺甲基)氨基]戊酰胺]
  参考文献：
  名称：

  ANTICOAGULANT REVERSAL AGENTS

  摘要：

  本发明揭示了新型抗凝血逆转化化合物，以及制备该化合物的方法、包括该化合物的药物组合物、使用该化合物逆转凝血抑制剂的抗凝血效果的方法，以及包括该化合物的诊断测定方法。

  公开号：

  US20130137702A1

文献信息

• LABELED COMPOUNDS AND METHODS OF IMAGING, DIAGNOSING CARTILAGE DISORDERS AND DISEASES, AND MONITORING CARTILAGE HEALTH USING LABELED AND UNLABELED COMPOUNDS
  申请人：Perosphere Inc.

  公开号：US20150133769A1

  公开（公告）日：2015-05-14

  Novel labeled compounds and metabolites thereof are disclosed, as well as pharmaceutical compositions including the compounds, and methods of using the labeled and unlabeled compounds, and specifically, 2-Amino-5-guanidino-pentanoic acid (3-4-[3-(2-amino-5-guanidino-pentanoylamino)-propyl]-piperazin-1-yl}-propyl)-amide and metabolites thereof, for imaging, detecting and assessing disorders and diseases, such as arthritis and, more specifically, osteoarthritis by tracking proteoglycan and glycosaminoglycan content of cartilage. Also, pharmaceutical compositions comprising labeled and/or unlabeled 1,4-Bis(3-aminopropyl)piperazine are disclosed and methods of using the same.
• Stable Glucagon Formulations
  申请人：PEROSPHERE INC.

  公开号：US20150374825A1

  公开（公告）日：2015-12-31

  Stabilized formulations containing a peptide, such as a glucagon, are described herein. The formulations are in the form of a solution or suspension, which exhibit ttle or no chemical degradation and/or aggregation of the peptide over an extended period of time. In some embodiments, the formulations are in the form of a solution containing the peptide, a solvent such as glycerin, and one or more thermal stabilizers. In other embodiments, the formulation is in the form of a suspension containing nano- and/or microparticles containing the peptide suspended in a non- aqueous, non-solvent. The nano- and/or microparticles can be prepared by micronizing the peptide with one or more humectants, such as salts, sugars, water-soluble polymers, and combinations thereof which increase the rate of dissolution of the peptide upon administration.
• COMPOSITIONS AND METHODS FOR WOUND CLOSURE
  申请人：THROMBO THERAPEUTICS, INC.

  公开号：US20200129448A1

  公开（公告）日：2020-04-30

  The current disclosure provides compositions and methods for wound closure. The disclosure provides an device comprising: a) a material with a surface comprising a modified fibrinogen or a modified fibrin, wherein the modified fibrinogen or modified fibrin is more resistant to fibrinolysis than an unmodified fibrinogen or an unmodified fibrin, respectively; and b) one or more dispersible fibrinolysis inhibitors in contact with the surface comprising a plasmin inhibitor; and c) optionally, a thrombin agent or platelets.
• US9522892B2
  申请人：——

  公开号：US9522892B2

  公开（公告）日：2016-12-20
• US9877961B2
  申请人：——

  公开号：US9877961B2

  公开（公告）日：2018-01-30